Naše iskustvo u lečenju botulizma
Sažetak
Uvod. Botulizam predstavlja neurointoksikaciju izazivanu toksinom koji luči Clostridium botulinum. Zbog visoke toksičnosti i smrtnosti, ovaj otrov se može koristiti kao biološko oružje. Prikaz bolesnika. Prikazano je šest bolesnika, srednje starosti 28,8 godina, koji su konzumirali konzervisanu hranu i kod kojih je dijagnoza postavljena na osnovu tipične kliničke slike. Najčešći simptomi, prisutni kod svih bolesnika bili su: zamagljen vid, dupla slika (diplopija), suva usta i opstipacija. Najduže lečenje primenjeno je kod bolesnika kod kojeg je bolest prepoznata tek posle 23 dana i koji nije primio serum antibotulinum. Svi bolesnici su primili antibiotike, a četvoro je primilo antitoksin. Neostigmin i klistir su korišćeni za lečenje poremećaja pokretljivosti creva i opstipacije. Zaključak. Dijagnoza botulizma bila je postavljena se na osnovu afebrilnosti, očuvanog stanja svesti, duple slike, suvih usta i podataka o konzumiranju sumnjive hrane. Polivalentni antibotulinski serum treba da se primeni što pre, jer smanjuje pojavu komplikacija, dužinu bolničkog lečenja i stopu smrtnosti.
Reference
Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 2004; 44: 167−93.
Konstantinović L, Krstic M, Kostic V, Rankovic J, Jovanovic M, Vrbić M. Clinical infectious diseases. Nis: University of Nis, 2001.(Serbian)
Eriksen T, Brantsaeter AB, Kiehl W, Steffens I. Botulism infection after eating fish in Norway and Germany: two outbreak re-ports. Euro Surveill 2004; 8(3): pii=2366.
Mayo Clinic Staff. Botulism treatments and drugs. Available from: http://www.mayoclinic.org/diseases-conditions/botulism/basics/treatment/con-20025875 [last ac-cesed 2015 September 1].
Rummel A, Eichner T, Weil T, Karnath T, Gutcaits A, Mahrhold S, et al. Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc Natl Acad Sci U S A 2007; 104(1): 359−64.
Dong M, Tepp WH, Liu H, Johnson, EA, Chapman ER. Mecha-nism of botulinum neurotoxin B and G entry into hippocam-pal neurons. J Cell Biol 2007; 179(7): 1511−22.
Christopher GW, Cieslak TJ, Pavlin JA, Eitzen EM Jr. Biological warfare. A historical perspective. JAMA 1997; 278(5): 412−7.
Ongrade J. Microbial warfare and bioterrorism Orv Hetil 2002; 143(33): 1935−9. (Hungarian)
Dembek ZF, Smith LA, Rusnak JM. Botulism: cause, effects, di-agnosis, clinical and laboratory identification, and treatment modalities. Disaster Med Public Health Prep 2007; 1(2): 122−34.
Rotz LD, Khan AS, Lillibridge SR, Ostroff SM, Hughes JM. Public health assessment of potential biological terrorism agents. Emerg Infect Dis 2002; 8(2): 225−30.
Centers for Disease Control and Prevention (CDC). Botulism. General information. Atlanta, Georgia: US Department of Health and Human Services, CDC; 2014.
Sobel J, Tucker N, Sulka A, McLaughlin J, Maslanka S. Foodborne botulism in the United States, 1990-2000. Emerg Infect Dis 2004; 10(9): 1606−11.
Leclair D, Fung J, Isaac-Renton JL, Proulx JF, May-Hadford J, Ellis A, et al. Foodborne botulism in Canada, 1985-2005. Emerg Infect Dis 2013; 19 (6): 961−8.
Bouvet P, Ruimy R, Bouchier C, Faucher N, Mazuet C, Popoff MR. An atypical Clostridium strain related to the Clostridium botu-linum group III strain isolated from a human blood culture. J Clin Microbiol 2014; 52(1): 339−43.
Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. Botulinum toxin as a biological weapon: med-ical and public-health management. JAMA 2001; 285(8): 1059−70.
Marcus N, Hourvitz A. Botulism disease. Harefuah 2002; 141(Spec No): 73−7, 120. (Hebrew)
Gutzwiller FS, Steffen R, Mathys P, Walser S, Schmid H, Mütsch M. Botulism: prevention, clinical diagnostics, therapy and possible threat. Dtsch Med Wochenschr 2008; 133(16): 840−5. (Ger-man)
Arora A, Sharma CM, Kumawat B, Khandelwal D. Rare presenta-tion of botulism with generalized fasciculations. Int J Appl Basic Med Res 2014; 4(1): 56−8.
Angulo FJ, Getz J, Taylor JP, Hendricks KA, Hatheway CL, Barth SS et al. A Large Outbreak of Botulism: The Hazardous Baked Potato. J Infect Dis 1998; 178(1): 172–7.
Sobel J. Botulism. Clin Infect Dis 2005; 41(8): 1167−73.
Khakshoor H, Moghaddam AS, Vejdani AH, Armstrong BK, Moshirfar M. Diplopia as the primary presentation of food-borne botulism. Oman J Ophthalmol 2012; 5(2): 109−11.
Vossen MG, Gattringer KB, Wenisch J, Khalifeh N, Koreny M, Spertini V, et al. The First Case(s) of Botulism in Vienna in 21 Years: A Case Report. Case Rep Infect Dis 2012; 2012: 438989.
Kotan D, Aygul R, Ceylan M, Yilikoglu Y. Clinically and electro-physiologically diagnosed botulinum intoxication. BMJ Case Rep 2013; 2013: pii: bcr0120125678.
Goonetilleke A, Harris JB. Clostridial neurotoxins. Neurol Neu-rosurg Psychiatry 2004; 75(Suppl 3): iii35−9.
Lonati D, Locatelli CA, Fenicia L, Anniballi F, Landri P, Giampreti A, et al. Fatal course of foodborne botulism in an eight-month old infant. Pediatr Rep 2011; 3(4): e31.
Lonati D, Locatelli CA, Fenicia L, Anniballi F, Landri P, Giampreti A, et al. Treatment of foodborne botulism in current clinical toxicology: authors' reply. Pediatr Rep 2012; 4(3): e27.
Robinson RF, Nahata MC. Management of botulism. Ann Pharmacother 2003; 37(1): 127−31.
Tacket CO, Shandera WX, Mann JM, Hargrett NT, Blake PA. Eq-uine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med 1984; 76(5): 794−8.
Thanongsaksrikul J, Chaicumpa W. Botulinum neurotoxins and botulism: a novel therapeutic approach. Toxins (Basel) 2011; 3(5): 469−88.
Momose Y, Asakura H, Kitamura M, Okada Y, Ueda Y, Hanabara Y, et al. Food-borne botulism in Japan in March 2012. Int J Infect Dis 2014; 24: 20−2.
Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med 1980; 69(4): 567−70.